Last reviewed · How we verify
NCT06135597
Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection
trial testing This is a blood test without regarding to intervention nor diagnostic tests in Aspergillosis in 100 participants. Status unknown.
31 December 2025
Quick facts
| Lead sponsor | Taipei Veterans General Hospital, Taiwan |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 23 March 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- This is a blood test without regarding to intervention nor diagnostic tests
Conditions studied
- Aspergillosis — all drugs for Aspergillosis →
Sponsor
Taipei Veterans General Hospital, Taiwan
Who can join
20 and older, any sex, with Aspergillosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to collect clinical cases and follow-up data from patients with chronic pulmonary aspergillosis, post-COVID-19 aspergillosis, and post-COVID-19 patients without aspergillosis. Using in vitro assays, we will measure the phagocytic function of neutrophils when stimulated by fungal hyphae, their ability to produce neutrophil extracellular traps (NETs), the expression of cell surface molecules at the time of enrollment, changes in cell surface molecule expression after stimulation with fungal hyphae, and the quantification of autoantibodies in the blood. This research will focus on the short-term (within 3 months), medium-term (6-12 months), and long-term (more than 12 months) changes in cell surface molecules and functions following infection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06135597
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aspergillosis
Currently open trials in the same condition.
- NCT05045391 — Pulmonary Aspergillosis in Tuberculosis Patients · active not recruiting
- NCT03828773 — PTX3-targeted Antifungal Prophylaxis · NA · recruiting
Other Taipei Veterans General Hospital, Taiwan trials
Trials by the same sponsor.
- NCT07463443 — Effectiveness of Chatbot for Improving Caregiving Outcomes in Primary Caregivers of Geriatric Pneumonia Patients: A Stud · NA · not yet recruiting
- NCT07400757 — Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease · NA · not yet recruiting
- NCT07362134 — Pulsed-Field Ablation for Recurrent Atypical Atrial Flutter · NA · enrolling by invitation
- NCT07473687 — Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room · recruiting
- NCT07344207 — GUARD-PH: Guided Use of AI-ECG for Risk Detection of PH in Surgery (GUARD-PH Trial) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06135597 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Veterans General Hospital, Taiwan
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06135597.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing